Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Prudential Financial Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Prudential Financial Inc trades at $123 (market cap $42.20B). The key difference: Prudential Financial Inc is the larger of the two by market cap, and Prudential Financial Inc pays a 4.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PRU | |
|---|---|---|
Market Cap | $29.60B | $42.20B |
Sector | Health | Financials |
52-Week High | $491.22 | $123.93 |
52-Week Low | $205.48 | $92.00 |
Enterprise Value | $27.56B | $70.98B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Prudential Financial (PRU) trades at $122.63, up 0.43% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q1 and Q2 2026. The company reported Q2 EPS of $4.08, exceeding expectations, driven by strength in PGIM and international segments. Valuation remains attractive with a P/E of 11.09 and P/S of 0.66, while a $1.40 quarterly dividend supports income appeal.
Outlook is cautiously optimistic given earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and regulatory changes in key markets like China. Analyst consensus is mixed with a Hold rating predominating, though institutional holdings show increased interest, suggesting potential for upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
